Junevity
CompanyUnited Kingdom
Junevity develops 2 assets, the furthest preclinical (JUN_01 in obesity). Mostly oligonucleotide acting on lipid and ceramide metabolism; based in the United Kingdom.
- 2
- Assets
- Furthest stage
- Preclinical
- Raised
- US$20m
- 0
- Trials
- 0
- Signals
Pipeline
2Cell reprogramming with siRNA.
Preclinical, Oligonucleotide, obesity, type 2 diabetes
Dual-targeted siRNA designed to restore gene networks.
Preclinical, Oligonucleotide, Lipid and ceramide metabolism, obesity
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Funding rounds and grants2
- People20
- Signals1
- Similar companies6